Drug Profile
TRV 027
Alternative Names: Beta-arrestin biased ligand - Trevena; MPS-418; TRV-120027; TRV027; β-arrestin biased ligand - TrevenaLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Trevena
- Developer Imperial College of Science, Technology and Medicine; National Heart, Lung and Blood Institute; Trevena
- Class Heart failure therapies; Oligopeptides; Vasodilators
- Mechanism of Action Angiotensin type 1 receptor antagonists; Beta-arrestin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Preclinical SARS-CoV-2 acute respiratory disease
- No development reported Blood coagulation disorders
- Discontinued Acute heart failure
Most Recent Events
- 05 Feb 2024 Vanderbilt University Medical Center completes the phase II/III NECTAR trial in COVID-2019 infections in USA (IV) (NCT04924660)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Blood-coagulation-disorders in United Kingdom (IV, Infusion)
- 11 May 2022 Trevena receives notice from the Data and Safety Monitoring Board (DSMB) for enrollment halt for TRV 027 as part of the ACTIV-4 Host Tissue platform study